REGN · Regeneron Pharmaceuticals Inc
Price
Snapshot
50 fields · last close| Market Cap | $86.84B |
| P/E | 20.26 |
| Float | 98.95M |
| Beta | 0.12 |
| Volatility | 5.0% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 76 |
| Price | 832.61 |
| Change | −1.29% |
| Prev Close | 843.47 |
| Open | 858.18 |
| Day Low | 837.63 |
| Day High | 859.34 |
| Avg Vol | 1 |
| Avg $ Vol | $567.5M |
| 52W High | 854.49 |
| 52W Low | 541.00 |
| 52W Pos | 93.0% |
| From High | −2.56% |
| From Low | +53.90% |
| Max DD 1Y | −26.05% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +2.09% |
| SMA 50 | +13.48% |
| SMA 200 | +13.81% |
| RSI (14) | 66.5 |
| Vol 30D | 30.9% |
| Vol 90D | 35.2% |
| 1Y Range | 541–854 |
| Daily bars | 506 |
| Perf Week | +4.43% |
| Perf Month | +9.74% |
| Perf Quarter | +34.15% |
| Perf Half Y | +10.27% |
| Perf Year | +49.60% |
| Perf YTD | +7.25% |
| Prev Day | −1.29% |
| Clavix | B+ |
| Debt / Eq | 0.09 |
| Curr Ratio | 4.13 |
| Int Cover | 19.1× |
| FCF Margin | 23.6% |
| Rev Growth | +16.7% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 10 / 35 |
What REGN does
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis.
It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency.
Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies.
It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies.
The company was incorporated in 1988 and is based in Tarrytown, New York.
Clavix risk grade
regraded every trading dayREGN grades B+, 76 of 100. Steadiest on Macro Resilience (72), most exposed on News Sentiment (42, fragile). 3 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 10 of 35 in Biotechnology by Clavix score.
How rough the ride is
| REGN | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.12 | 0.50 |
| Volatilityannualized | 5.0% | 13.2% |
| Max drawdown, past yearworst peak-to-trough fall | −26.1% | — |
| Typical daily movemedian absolute daily change | 1.08% | — |
| Days beyond ±3%of the last 252 sessions | 3313% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| REGN | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.12 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| REGN | |
|---|---|
| 1 week | +4.4% |
| 1 month | +9.7% |
| Year to date | +7.3% |
| 1 year | +49.6% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| REGN | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 20 Aug |
| Average score0 most bearish, 100 most bullish | 29 |
| Bullish · bearisharticles above 60 · below 40 | 5 · 25 |
| Directionarticles whose tone is improving vs worsening | 5 ↑ 25 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| REGN | |
|---|---|
| Revenue growthyear over year | +16.7% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Biotechnology
36 companies| Metric | REGN | Sector spread | Median |
|---|---|---|---|
| Beta | 0.12 | 0.50 | |
| Volatility | 5.0% | 13.2% | |
| P/E | 20.26 | 22.77 | |
| Debt / equity | 0.09 | 0.24 | |
| Current ratio | 4.13 | 3.73 | |
| FCF margin | 23.6% | 29.1% | |
| Interest coverage | 19.1× | -0.2× |
Recent news
most recent scored articles · the chip is the article’s score · click to openA federal securities class action lawsuit has been filed against Regeneron Pharmaceuticals, covering investors who purchased shares between August 1, 2025 and May 15, 2026. The law firm Faruqi & Faruqi is reminding investors that September 14, 2026 is the deadline to seek the lead plaintiff role in the case.
A securities fraud class action lawsuit has been filed against Regeneron Pharmaceuticals (REGN) over disclosures about the protocol and ultimate failure of a Phase 3 clinical trial for a melanoma therapy. The law firm Hagens Berman is alerting investors to the pending case.
A law firm is telling investors they can step forward to lead a class action lawsuit accusing Regeneron Pharmaceuticals (REGN) of securities fraud under federal law.
Law firm Faruqi & Faruqi is reminding Regeneron investors of a September 14, 2026 deadline to seek the lead plaintiff role in a federal securities class action lawsuit filed against the company. The lawsuit covers investors who bought REGN securities between August 1, 2025 and May 15, 2026.
A law firm has filed a class action lawsuit against Regeneron Pharmaceuticals and certain of its officers, and is urging investors who may have been harmed to take action. The article does not detail the specific allegations behind the suit.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc | B+ | $121.1B | 32.51 | 0.27 | Compare |
| MRNA | Moderna Inc | F | $59.43B | — | 1.22 | Compare |
| NTRA | Natera Inc | B- | $47.23B | — | 1.61 | Compare |
| RVMD | Revolution Medicines Inc | B- | $45.20B | — | 1.44 | Compare |
| GILD | Gilead Sciences, Inc | A- | $187.5B | 21.85 | 0.40 | Compare |
| ALNY | Alnylam Pharmaceuticals Inc | C | $35.39B | 44.28 | 0.34 | Compare |
| BIIB | Biogen Inc | B+ | $33.17B | 39.72 | 0.12 | Compare |
| AMGN | Amgen Inc | A- | $240.1B | 27.38 | 0.45 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.